{
  "first_published_at": "2013-08-07", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON300399", 
  "title": "Caffeine for apnoea of prematurity: all products to be named and prescribed as caffeine citrate", 
  "tags": "{\"parsed_therapeutic\": [\"anaesthesia-intensive-care\", \"obstetrics-gynaecology-fertility\", \"paediatrics-neonatology\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Anaesthesia and intensive care\", \"Obstetrics, gynaecology and fertility\", \"Paediatrics and neonatology\"]}", 
  "_document_number": 61, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "anaesthesia-intensive-care", 
    "obstetrics-gynaecology-fertility", 
    "paediatrics-neonatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Caffeine for apnoea of prematurity: all products to be named and prescribed as caffeine citrate</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>In order to minimise potential risk to premature newborns when prescribing or dispensing, the name of caffeine products supplied by Viridian Pharma Limited is being changed to caffeine citrate. This change brings the Viridian products in line with the naming of other products available on the UK market (ie, which are already named in the salt form as caffeine citrate). All product doses should be prescribed as caffeine citrate, taking into account the different strengths of the marketed products&#8212;see below<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Caffeine (citrate) is authorised for treatment of apnoea of premature newborns and may be given orally or intravenously. In order to minimise the risk of prescribing or dosing errors, the Commission on Human Medicines has advised that all products be named consistently and prescribed as caffeine citrate.</p>\n\n<p>In line with this advice, the naming of products available from Viridian Pharma is being changed to:</p>\n\n<ul>\n<li>Caffeine citrate 10 mg/mL solution for injection (previously called caffeine 5&#160;mg/mL solution for injection)</li>\n\n<li>Caffeine citrate 10 mg/mL oral solution (previously called caffeine 5 mg/mL oral solution)</li>\n</ul>\n\n<p>There is no change to the formulation of these products. The new packaging of Viridian Pharma products displaying the new name may not be immediately available (expected to be available from October 2013). However, all packaging (current and new) has dual labelling, which clearly states the strengths of both caffeine and caffeine citrate.</p>\n\n<p>The <a target=\"_blank\" href=\" http://www.bnf.org/bnf/search.htm?q=caffeine\">British National Formulary for Children</a> and the <a target=\"_blank\" href=\"http://www.pharmacopoeia.co.uk/\">British Pharmacopoeia</a> contain monographs in the name of caffeine citrate.</p>\n\n<p><strong>Prescribing of caffeine citrate products</strong></p>\n\n<p>Doses specified when prescribing should always be expressed as caffeine citrate because of a risk of confusion and potential for dosing errors (2 mg caffeine citrate is equivalent to 1 mg caffeine). It is also important to note that marketed products are available in different strengths: Peyona (caffeine citrate 20 mg/mL) is double that of products from Viridian Pharma (caffeine citrate 10 mg/mL).</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Always state dose in terms of caffeine citrate when prescribing</li>\n\n<li>Take care when prescribing and dispensing because marketed products are available in different strengths: Peyona is twice the strength of products from Viridian Pharma</li>\n\n<li>Caffeine citrate is for use in neonatal intensive care units only, and treatment must be initiated under the supervision of a physician experienced in neonatal intensive care</li>\n\n<li>Measurement of baseline caffeine levels, monitoring of plasma caffeine concentrations, and dose adjustments during treatment are advisable&#8212;particularly in neonates with: insufficient response; signs of toxicity; possible pre-existing caffeine in the blood; or those with increased risk of elevated plasma concentrations</li>\n\n<li>Please remember to report suspected adverse reactions with caffeine citrate through the Yellow Card Scheme online at <a target=\"_blank\" href=\"http://www.mhra.gov.uk/yellowcard \">http://www.mhra.gov.uk/yellowcard</a> &#160;</li>\n</ul>\n</div>\n\n<p>For further information, refer to the <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?indexChar=C#retainDisplay\">Summary of Product Characteristics</a> or technical prescribing information for the product.</p>\n\n<p><em>Article citation: Drug Safety Update vol 7 issue 1, August 2013: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Caffeine (citrate) is authorised for treatment of apnoea of premature newborns and may be given orally or intravenously. In order to minimise the risk of prescribing or dosing errors, the Commission on Human Medicines has advised that all products be named consistently and prescribed as caffeine citrate.</p>\n\n<p>In line with this advice, the naming of products available from Viridian Pharma is being changed to:</p>\n\n<ul>\n<li>Caffeine citrate 10 mg/mL solution for injection (previously called caffeine 5&#160;mg/mL solution for injection)</li>\n\n<li>Caffeine citrate 10 mg/mL oral solution (previously called caffeine 5 mg/mL oral solution)</li>\n</ul>\n\n<p>There is no change to the formulation of these products. The new packaging of Viridian Pharma products displaying the new name may not be immediately available (expected to be available from October 2013). However, all packaging (current and new) has dual labelling, which clearly states the strengths of both caffeine and caffeine citrate.</p>\n\n<p>The <a target=\"_blank\" href=\"http://www.bnf.org/bnf/search.htm?q=caffeine\">British National Formulary for Children</a> and the <a target=\"_blank\" href=\"http://www.pharmacopoeia.co.uk/\">British Pharmacopoeia</a> contain monographs in the name of caffeine citrate.</p>\n\n<p><strong>Prescribing of caffeine citrate products</strong></p>\n\n<p>Doses specified when prescribing should always be expressed as caffeine citrate because of a risk of confusion and potential for dosing errors (2 mg caffeine citrate is equivalent to 1 mg caffeine). It is also important to note that marketed products are available in different strengths: Peyona (caffeine citrate 20 mg/mL) is double that of products from Viridian Pharma (caffeine citrate 10 mg/mL).</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Always state dose in terms of caffeine citrate when prescribing</li>\n\n<li>Take care when prescribing and dispensing because marketed products are available in different strengths: Peyona is twice the strength of products from Viridian Pharma</li>\n\n<li>Caffeine citrate is for use in neonatal intensive care units only, and treatment must be initiated under the supervision of a physician experienced in neonatal intensive care</li>\n\n<li>Measurement of baseline caffeine levels, monitoring of plasma caffeine concentrations, and dose adjustments during treatment are advisable&#8212;particularly in neonates with: insufficient response; signs of toxicity; possible pre-existing caffeine in the blood; or those with increased risk of elevated plasma concentrations</li>\n\n<li>Please remember to report suspected adverse reactions with caffeine citrate through the Yellow Card Scheme online at <a target=\"_blank\" href=\"http://www.mhra.gov.uk/yellowcard\">http://www.mhra.gov.uk/yellowcard</a> &#160;</li>\n</ul>\n</div>\n\n<p>For further information, refer to the <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?indexChar=C#retainDisplay\">Summary of Product Characteristics</a> or technical prescribing information for the product.</p>\n\n<p><em>Article citation: Drug Safety Update vol 7 issue 1, August 2013: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-08-01", 
  "date_last_modified": "2013-08-07", 
  "_assets": [], 
  "_item_id": 61, 
  "summary": "In order to minimise potential risk to premature newborns when prescribing or dispensing, the name of caffeine products supplied by Viridian Pharma Limited is being changed to caffeine citrate. This change brings the Viridian products in line with the naming of other products available on the UK market (ie, which are already named in the salt form as caffeine citrate). All product doses should be prescribed as caffeine citrate, taking into account the different strengths of the marketed products—see below", 
  "body": "Article date: August 2013\n\nCaffeine (citrate) is authorised for treatment of apnoea of premature newborns and may be given orally or intravenously. In order to minimise the risk of prescribing or dosing errors, the Commission on Human Medicines has advised that all products be named consistently and prescribed as caffeine citrate.\n\nIn line with this advice, the naming of products available from Viridian Pharma is being changed to:  \n  \n  * Caffeine citrate 10 mg/mL solution for injection (previously called caffeine 5 mg/mL solution for injection)  \n  * Caffeine citrate 10 mg/mL oral solution (previously called caffeine 5 mg/mL oral solution)  \n  \nThere is no change to the formulation of these products. The new packaging of Viridian Pharma products displaying the new name may not be immediately available (expected to be available from October 2013). However, all packaging (current and new) has dual labelling, which clearly states the strengths of both caffeine and caffeine citrate.\n\nThe [British National Formulary for Children](http://www.bnf.org/bnf/search.htm?q=caffeine) and the [British Pharmacopoeia](http://www.pharmacopoeia.co.uk/) contain monographs in the name of caffeine citrate.\n\nPrescribing of caffeine citrate products\n\nDoses specified when prescribing should always be expressed as caffeine citrate because of a risk of confusion and potential for dosing errors (2 mg caffeine citrate is equivalent to 1 mg caffeine). It is also important to note that marketed products are available in different strengths: Peyona (caffeine citrate 20 mg/mL) is double that of products from Viridian Pharma (caffeine citrate 10 mg/mL).\n\nAdvice for healthcare professionals:  \n  \n  * Always state dose in terms of caffeine citrate when prescribing  \n  * Take care when prescribing and dispensing because marketed products are available in different strengths: Peyona is twice the strength of products from Viridian Pharma  \n  * Caffeine citrate is for use in neonatal intensive care units only, and treatment must be initiated under the supervision of a physician experienced in neonatal intensive care  \n  * Measurement of baseline caffeine levels, monitoring of plasma caffeine concentrations, and dose adjustments during treatment are advisable—particularly in neonates with: insufficient response; signs of toxicity; possible pre-existing caffeine in the blood; or those with increased risk of elevated plasma concentrations  \n  * Please remember to report suspected adverse reactions with caffeine citrate through the Yellow Card Scheme online at <http://www.mhra.gov.uk/yellowcard>    \n  \nFor further information, refer to the [Summary of Product Characteristics](http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?indexChar=C#retainDisplay) or technical prescribing information for the product.\n\nArticle citation: Drug Safety Update vol 7 issue 1, August 2013: A2.\n"
}